Anzeige
Erschienen in:
19.06.2017 | Original Article – Cancer Research
The constitutive protease release by primary human acute myeloid leukemia cells
Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2017
Einloggen, um Zugang zu erhaltenAbstract
Introduction
Acute myeloid leukemia (AML) cells show constitutive release of matrix metalloproteases and their inhibitors. We now investigated this constitutive release of protease/protease regulators associated with carcinogenesis (ADAM12, uPA, cystatin B), angiogenesis (serpin E1, uPA, CD147), cancer cell migration (uPA, cystatin C), coagulation (ADAM TS13, serpin C1), inflammation (fetuin A, caspase 1, cystatin C), monocytic differentiation (CFD) or regulation of hematopoiesis (neutrophil elastase).
Methods
AML blasts from 79 consecutive patients were cultured in serum-free medium and mediator levels determined in culture supernatants.
Results
Detectable release of serpin C1 and E1, cystatin B and C, CD147 and uPA was seen for most patients. These mediators together with fetuin A, caspase 1, and CFD were included in a hierarchical clustering analysis and three patient subsets were identified (high, intermediate, and low release). High levels were associated with monocytic differentiation. Global gene expression analyses showed increased levels of several zinc finger proteins for low-release patients and high expression of several cell surface molecules, ATPases, and calcium-binding proteins for high-release patients. Constitutive release of several mediators was also seen for normal hematopoietic cells and mesenchymal stem cells. In cocultures of the latter and AML blasts, the release level for most mediators was altered to resemble the levels of the mesenchymal cells cultured alone.
Conclusion
Differences in constitutive release of protease/protease regulators are a part of the disease heterogeneity in AML.